QNRX vs. NRXS, PSTV, PETV, NXGL, IINN, BDMD, XAIR, INBS, MHUA, and DHAI
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include NeurAxis (NRXS), Plus Therapeutics (PSTV), PetVivo (PETV), NexGel (NXGL), Inspira Technologies OXY B.H.N. (IINN), Baird Medical Investment (BDMD), Beyond Air (XAIR), Intelligent Bio Solutions (INBS), Meihua International Medical Technologies (MHUA), and DIH Holding US (DHAI). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs. Its Competitors
NeurAxis (NASDAQ:NRXS) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.
NeurAxis currently has a consensus price target of $7.00, suggesting a potential upside of 152.71%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeurAxis is more favorable than Quoin Pharmaceuticals.
In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than NeurAxis. MarketBeat recorded 1 mentions for Quoin Pharmaceuticals and 0 mentions for NeurAxis. Quoin Pharmaceuticals' average media sentiment score of 1.87 beat NeurAxis' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.
11.8% of NeurAxis shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 26.4% of NeurAxis shares are held by company insiders. Comparatively, 3.7% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Quoin Pharmaceuticals has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.
Quoin Pharmaceuticals has lower revenue, but higher earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NeurAxis has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
Summary
NeurAxis beats Quoin Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 7/26/2025 by MarketBeat.com Staff
